Summary
MedTech teams have more claims, referral, procedure, payer, and adoption data than ever. The advantage now belongs to teams that translate it into action reps can use.
Most medical technology (MedTech) commercial teams sit on an enormous amount of data. Claims data, procedure data, referral intelligence, reimbursement detail, customer relationship management (CRM) records, and competitive analysis are all within reach. The shortage is not information.
Much of that information never reaches the people closest to the revenue moment in a usable form. It stays trapped in dashboards, spreadsheets, planning decks, and disconnected CRM notes.
McKinsey has documented both the opportunity and the upside. The firm notes that MedTech companies now have access to more data and advanced analytics than ever, applied to commercial work such as microsegmentation, account insights, propensity-to-buy models, account prioritization, next best actions, tender pricing, and churn prevention. Early adopters are seeing real movement, with McKinsey reporting a 1.5 to 2.0 times increase in customer funnel metrics, 50 percent higher proposal conversion rates, and up to 10 percent increases in incremental revenue.
The thesis is direct. MedTech commercial teams already have abundant data. What they lack is an operating model that translates market intelligence into field execution, seller confidence, customer trust, and measurable revenue. The next advantage will come from turning clinical context, claims intelligence, referral patterns, payer dynamics, adoption signals, customer proof, and AI recommendations into actions a representative can use.
The commercial challenge is moving from insight to action
Commercial strategy in MedTech usually gets built centrally. Execution happens territory by territory, account by account, and representative by representative. The breakdown occurs when strategy never reaches the field in the form leaders intended.
The category is beginning to name this gap more directly. MedScout, a MedTech commercial intelligence company, has described the problem as the distance between centrally developed commercial strategy and field execution. Its public materials for Strategies, its AI agents that analyze referral networks, procedure volumes, and payer dynamics, point to a broader market shift. Commercial intelligence becomes more valuable when it reaches the field as prioritized territory action, rather than as another report.
MedScout is one signal inside a growing category. The pattern behind all of them matters more than any single vendor. The opportunity is not the possession of data. The opportunity is the ability to answer a field-level question quickly: where should the representative focus, why now, what is the account context, and what action moves the opportunity forward.
MedTech commercialization is too complex for generic motions
Artificial Intelligence (AI) cannot rescue a commercial model that ignores how MedTech actually sells. A MedTech buying decision is rarely a simple vendor comparison.
Commercial teams have to connect provider need, procedure volume, care setting, reimbursement, clinical evidence, the patient pathway, hospital economics, the competitive installed base, and relationship history. Each account carries a different version of that puzzle. Positioning has to land with clinicians, health systems, patients, and payers at the same time, while aligning to market access and reimbursement reality.
That complexity reshapes the marketing job. Marketing cannot stop at describing product value. It has to help the commercial team translate product value into the specific clinical, operational, economic, and adoption context of each account.
AI is becoming a differentiator, and readiness is uneven
Artificial Intelligence (AI) investment in MedTech is rising, and operational readiness is lagging behind it. The gap is measurable.
Deloitte’s 2026 Life Sciences Outlook Survey found that just 15 percent of surveyed MedTech executives said their organizations currently operate AI at scale. Intent for the year ahead runs much higher. For 2026, 53 percent said they would invest in AI-enabled platforms, while 47 percent intend to deploy AI tools to improve operational efficiencies.
Deloitte also identifies where execution stalls, citing data quality, regulatory compliance, and change management. The most prepared leaders invest first in data governance, talent, playbooks, and standardized processes. AI becomes a competitive differentiator in MedTech only when companies pair speed with governance, privacy, process maturity, and clear human roles.
Product-side AI is ahead of commercial-side AI
MedTech has embraced AI inside its products. The same discipline has not yet reached most commercial operations, and that imbalance is the opportunity.
The product side is already visible and regulated. The U.S. Food and Drug Administration (FDA) maintains a public list of AI-enabled medical devices authorized for marketing, which signals how far clinical AI has advanced. The financial case for going further is large. McKinsey estimates that MedTech companies could capture 14 billion to 55 billion dollars per year in productivity value and add 50 billion dollars or more in annual revenue from product and service innovations. McKinsey adds that the sector’s data-enabled products and numerous repetitive workflows make generative AI especially compelling.
The gap is difficult to defend. An industry that builds AI-enabled diagnostics and connected devices still leaves many commercial teams dependent on stale spreadsheets, manual account research, and disconnected CRM activity. The commercial organization deserves the same engineering attention as the product.
Field teams need context more than they need more information
A representative does not need 50 more fields in a CRM. A representative needs to understand why an account matters, what changed, which providers or facilities deserve attention, which proof point fits, and which conversation is credible.
McKinsey’s own MedTech work points to the same truth. It found that full value gets captured only through close collaboration between experienced representatives, who bring business judgment, and data scientists, who turn that judgment into analytics. McKinsey describes analytics translators who served as liaisons between the technical and business sides of a project. The insight has to be translated for the field, not just generated for a dashboard.
That is the operating purpose of weekly signal work. I have been building a weekly signal intelligence process that compares sales, marketing, website, advertising, and intent activity across weeks. The point is not to collect more data. The point is to identify account patterns, weigh signal quality, draft sales-ready context, and help sellers understand which companies deserve attention and why. Commercial intelligence earns its value when it helps the field show up smarter, and not merely faster.
The missing layer is translation logic
MedTech teams need a defined layer between raw data and field execution. That layer interprets the signal, applies commercial strategy, builds account context, and recommends a useful next action. I call it the MedTech Translation Layer.
The layer has one practical job. It turns a data point into a sentence a representative can act on. Without this layer, a company can have accurate data and still create weak field execution. A signal becomes field action only after it passes through seven steps.
- Signal. A market event appears, such as procedure volume, referral movement, payer mix, an adoption pattern, a care setting, or a competitive shift.
- Commercial context. The team connects the signal to a segment, product line, territory, or strategic priority.
- Account meaning. The team establishes why this account matters now.
- Stakeholder logic. The team identifies which clinician, facility, service line, administrator, or economic buyer is likely to care.
- Proof requirement. The team selects the evidence, outcome, financial case, or customer result that reduces perceived risk.
- Sales action. The team defines what the representative should do next.
- Feedback loop. The team records whether the action produced a meeting, opportunity, conversion, expansion, or lesson.
The translation layer turns claims data into commercial movement. Without it, teams keep asking representatives to interpret strategy alone, in the field, under time pressure.
CRM integration matters because execution happens in the workflow
Account strategy that never reaches the systems sellers use will not reliably change behavior. AI-generated insight has to land inside CRM, account planning, territory management, enablement, and follow-up.
Bain’s 2025 Commercial Excellence and Revenue Growth Agenda, based on a survey of more than 1,200 senior commercial executives across 18 industries, measured the gap. Bain found that while more than 80 percent of respondents claim to run structured, repeatable sales and marketing activities, 70 percent do not effectively integrate their sales plays into their technology, so only about 20 percent have realized full value. The foundation is often missing too. Bain reported that more than half of commercial organizations have not yet set up adequate data foundations to optimize the technology, citing incomplete or low-quality data and improperly configured tools.
MedTech leaders face the same operating constraint. A commercial strategy becomes operational only when it changes what the field sees, prioritizes, says, and measures inside the systems they already use.
Better data does not build trust by itself
Data can identify the opportunity. Earning trust is a separate task, and complex healthcare buying still runs on human confidence.
Gartner’s 2026 research captures the balance. It found that 45 percent of business-to-business (B2B) buyers used generative AI during a recent purchase, while 69 percent prefer to validate AI-generated insights with sales reps. Buyers drew on an average of seven information sources along the way. The seller’s role is shifting from first source of information to source of validation and confidence at the decisive moments.
The implication for MedTech is direct. The best commercial intelligence should make human conversations better. It should help sales teams validate the opportunity, reduce uncertainty, and connect innovation to the clinicians and patients most likely to benefit.
Customer proof has to travel with the signal
A signal tells the representative where to look. Proof tells the buyer why the conversation deserves attention.
In MedTech, that proof may include patient impact, procedural efficiency, financial return, physician adoption, service-line growth, or peer evidence. Each account weighs proof differently, so the same outcome story will not move every buyer. The strongest commercial intelligence connects the account signal to the proof most likely to reduce that buyer’s perceived risk.
This is where customer outcomes become a revenue asset rather than a marketing asset. Proof that sits on a website helps no one in a live conversation. Proof routed to the right account, at the right moment, helps sales answer the buyer’s hardest question: why should we believe this will work for us?
The future MedTech marketer is a commercial translator
The marketing leader’s job in MedTech is expanding well past brand, content, and demand generation. Marketing now has to translate complex market intelligence into positioning, proof, enablement, seller confidence, and measurable pipeline.
McKinsey’s 2026 healthcare research points to where the difficulty concentrates. It found that high performers pursue a domain-based, end-to-end workflow approach, while the harder work has shifted from proof of concept toward embedding AI into complex, legacy systems. Integration and internal capability gaps become the binding constraints. The marketer who can connect category narrative, product value, customer outcomes, AI-enabled intelligence, and field execution is the one who makes thought leadership pipeline-relevant.
The strategic implication: the winner will translate faster
MedTech commercial teams have more data than they can interpret by hand. They also face more pressure to prove value, more complex buying groups, more constrained clinical access, more reimbursement scrutiny, and a higher bar for precise field execution.
The companies that pull ahead will translate intelligence into action faster and more consistently than their competitors. They will know which providers to prioritize. They will understand why a signal matters. They will equip representatives with credible context. They will connect customer proof to the right moment, and they will measure whether the action created movement.
That is the real MedTech marketing opportunity. The advantage is not more data, and it is not another dashboard. The advantage is better translation, built into the operating model so it survives volume, turnover, and complexity.
So the question for any MedTech commercial leader is direct. When your next strong market signal appears, can your system turn it into a specific, credible action in a representative’s hands, or does it stop at a dashboard nobody opens?
